Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDNAF Stock Forecast 2025-2026
$0.66
Current Price
$52.75M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDNAF Price Targets
+807.7%
To High Target of $6.00
+543.0%
To Median Target of $4.25
+278.2%
To Low Target of $2.50
MDNAF Price Momentum
-2.9%
1 Week Change
-18.5%
1 Month Change
-51.1%
1 Year Change
-42.1%
Year-to-Date Change
-65.9%
From 52W High of $1.94
+10.2%
From 52W Low of $0.60
📊 TOP ANALYST CALLS
Did MDNAF Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Medicenna is one of their latest high-conviction picks.
Latest MDNAF Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, MDNAF has a bullish consensus with a median price target of $4.25 (ranging from $2.50 to $6.00). Currently trading at $0.66, the median forecast implies a 543.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDNAF Analyst Ratings
4
Buy
0
Hold
0
Sell
MDNAF Price Target Range
Low
$2.50
Average
$4.25
High
$6.00
Current: $0.66
Latest MDNAF Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDNAF.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Dec 18, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Dec 17, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Sep 10, 2020 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Medicenna Therapeutics Corp. (MDNAF) Competitors
The following stocks are similar to Medicenna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medicenna Therapeutics Corp. (MDNAF) Financial Data
Medicenna Therapeutics Corp. has a market capitalization of $52.75M with a P/E ratio of -1.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -149.1%.
Valuation Metrics
Market Cap
$52.75M
Enterprise Value
$16.11M
P/E Ratio
-1.8x
PEG Ratio
-3.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+58.1%
Current Ratio
10.1x
Debt/Equity
1.0x
ROE
-149.1%
ROA
-42.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Medicenna Therapeutics Corp. (MDNAF) Business Model
About Medicenna Therapeutics Corp.
What They Do
Develops advanced immunotherapies for cancer.
Business Model
Medicenna Therapeutics Corp. operates as a clinical-stage biotechnology company, generating revenue primarily through the development and commercialization of its innovative Superkine therapeutics. The company focuses on creating interleukin-based treatments that enhance the immune response against cancer and other diseases, aiming to bring novel therapies to market as they progress through clinical trials.
Additional Information
Medicenna's pipeline includes promising candidates like MDNA11 and MDNA55, targeting challenging conditions such as glioblastoma. The company emphasizes scientific rigor and aims to address significant unmet medical needs, while maintaining a commitment to advancing cytokine biology and patient-centered outcomes in therapeutic development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Fahar Merchant Ph.D.
Country
Canada
IPO Year
2017
Website
www.medicenna.comMedicenna Therapeutics Corp. (MDNAF) Latest News & Analysis
Latest News
Quick Summary
Medicenna Therapeutics will present data from its Phase 1/2 ABILITY-1 trial and pre-clinical results for MDNA113 at the AACR Annual Meeting 2025, scheduled for April 25-30 in Chicago.
Why It Matters
Presentation of new trial data can significantly impact Medicenna's stock price, reflecting investor confidence in its innovative cancer therapies and potential market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
4 months ago
Quick Summary
MDNA11 shows a 78% disease control rate in combination with Merck's KEYTRUDA in the Phase 1/2 ABILITY-1 trial, with one complete response and one partial response.
Why It Matters
A 78% disease control rate in the MDNA11 and KEYTRUDA trial indicates strong potential for effective cancer treatment, likely boosting investor confidence and interest in the companies involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
4 months ago
Quick Summary
Medicenna Therapeutics will participate in two investor conferences in February 2025 and will hold one-on-one meetings with investors. The company focuses on immunotherapy for cancer and autoimmune diseases.
Why It Matters
Medicenna's participation in investor conferences signals potential growth opportunities and increased visibility, which could influence stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MDNA11 outperformed a combination of immune checkpoint inhibitors in preventing metastasis and achieving long-term survival in a mouse model of triple negative breast cancer (TNBC).
Why It Matters
MDNA11's superior performance over established treatments in a preclinical model may signal a potential breakthrough in TNBC therapy, influencing future market opportunities and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A 70-year-old patient with advanced chemo-refractory anal cancer achieved a complete response in 8 weeks using MDNA11 alongside Merck's KEYTRUDA® (pembrolizumab).
Why It Matters
Positive patient outcomes from MDNA11 combined with KEYTRUDA could boost market confidence in these therapies, potentially increasing stock value for MDNA and Merck.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MDNA11 demonstrates significant survival benefits in preclinical glioblastoma models, enhancing CD8+ T and NK cell activity.
Why It Matters
MDNA11's preclinical success in glioblastoma could indicate a promising cancer treatment, potentially boosting investor confidence and driving stock value for related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDNAF Stock
What is Medicenna Therapeutics Corp.'s (MDNAF) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Medicenna Therapeutics Corp. (MDNAF) has a median price target of $4.25. The highest price target is $6.00 and the lowest is $2.50.
Is MDNAF stock a good investment in 2025?
According to current analyst ratings, MDNAF has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDNAF stock?
Wall Street analysts predict MDNAF stock could reach $4.25 in the next 12 months. This represents a 543.0% increase from the current price of $0.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medicenna Therapeutics Corp.'s business model?
Medicenna Therapeutics Corp. operates as a clinical-stage biotechnology company, generating revenue primarily through the development and commercialization of its innovative Superkine therapeutics. The company focuses on creating interleukin-based treatments that enhance the immune response against cancer and other diseases, aiming to bring novel therapies to market as they progress through clinical trials.
What is the highest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The highest price target for MDNAF is $6.00 from at , which represents a 807.7% increase from the current price of $0.66.
What is the lowest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The lowest price target for MDNAF is $2.50 from at , which represents a 278.2% increase from the current price of $0.66.
What is the overall MDNAF consensus from analysts for Medicenna Therapeutics Corp.?
The overall analyst consensus for MDNAF is bullish. Out of 1 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.25.
How accurate are MDNAF stock price projections?
Stock price projections, including those for Medicenna Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 12:49 PM UTC